QIAGEN is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). Further information can be found at http://www.qiagen.com.
Hookipa Biotech and Vaxwave® platforms have shown promising abilities to deliver not only high antibody responses, but also necessary levels of T cell responses, currently missing in most vaccine and therapeutic approaches. Hookipa’s vectors can also be administered multiple times providing even greater immune protection.
MSD is a global healthcare leader working to help the world be well. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. MSD has been working to discover and develop vaccines for more than a century. Our unique vaccines have helped prevent a number of diseases. Today, we remain dedicated to the complex business of researching and producing vaccines.
VBI Vaccines is a Cambridge, Massachusetts based biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is currently in a Phase I clinical study to evaluate the safety, tolerability and immunological proof of concept of its enveloped virus-like particle (eVLP) based CMV vaccine. Preliminary results are expected mid-year 2017.
DiaSorin is a global leader in the market for in vitro diagnostics. For over 40 years the Group has been developing, producing and commercializing diagnostic tests for a wide range of clinical areas. Test are designed for hospital and private testing laboratories, in the markets of immunodiagnostics and molecular diagnostics.
Novartis is a global healthcare company that provides solutions to adress the evolving needs of patients in a growing and aging population, and the constant changing healthcare needs. Our strategy is focused on achieving better treatment outcomes for patients by science based innovation. Our goal is to provide a meaningful contribution to healthcare environment.
Janssen Vaccines is committed to developing first-in-class or best-in-class vaccines for some of the world’s most life-threatening infectious diseases, such as Ebola, RSV, HIV, Polio and ExPEC.
Immudex manufactures MHC Dextramers, the leading MHC multimer reagent for detection of antigen-specific T cells for research and in vitro diagnostics. Our CMV immune monitoring kit are IVD cleared in EU and USA.